Dementia

Results, Increased incidence of MCI and AD in vaccinated individuals, particularly those receiving mRNA vaccines, within three months post-vaccination. mRNA vaccine group AD, Odds Ratio: p = MCI, Odds Ratio: p less than No significant relationship was found with vascular dementia or Parkinson’s disease. October 2022, Biden receives new COVID-19 booster A potential association between COVID-19 vaccination and development of Alzheimer’s disease 28 May 2024 Background Concerns about vaccine side effects, particularly potential links to neurodegenerative diseases such as Alzheimer’s disease (AD). Aim This study investigates the association between COVID-19 vaccination and the onset of AD, and it’s prodromal state, mild cognitive impairment (MCI). Design A nationwide, retrospective cohort study Korean National Health Insurance Service. Data recorded 3 months after vaccination Methods Seoul, South Korea, analyzed data from a random 50% sample, aged 65 and above, n = 558,017. Vaccinated group Unvaccinated group Patients with vascular dementia or Parkinson’s disease served as controls. Conclusions Preliminary evidence suggests a potential link between COVID-19 vaccination, particularly mRNA vaccines, and increased incidences of AD and MCI. Need for further research to elucidate the relationship between vaccine-induced immune responses and neurodegenerative processes, advocating for continuous monitoring and investigation into the vaccines’ long-term neurological impacts. Roh JH, Jung I, Suh Y, Kim MH. A potential association between COVID-19 vaccination and development of alzheimer’s disease. QJM. 2024 May 28:hcae103. doi: Epub ahead of print. PMID: 38806183.